## ELV: Elevance Health, Inc. - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_10 at 7.8% exceeds exhaustion threshold (8.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops.

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($339.23)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_10 drops below exhaustion threshold

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 2)

**1. Bronstein, Gewirtz & Grossman, LLC Is Investigating Elevance Health, Inc. (ELV) And Encourages Shareholders to Connect**
- Source: MyStateline | 20251214T160757 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elevance Health, Inc. (NYSE:ELV). The investigation focuses on whether Elevance and its officers engaged in corporate wrongdoing, particularly for investors who bought securities before April 18, 2024, and still hold them. The firm encourages affected shareholders to connect through their website to assist in the investigation.

**2. Bronstein, Gewirtz & Grossman, LLC Is Investigating Elevance Health, Inc. (ELV) And Encourages Shareholders to Connect**
- Source: FOX 8 News | 20251214T160753 | Somewhat-Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Elevance Health, Inc. (ELV) for potential corporate wrongdoing, focusing on actions prior to April 18, 2024. The firm encourages shareholders who purchased Elevance securities before this date and still hold them to connect for more information and to assist in the investigation. The representation is on a contingency fee basis with no upfront cost to investors.

**3. AM Best Takes Various Credit Rating Actions on Elevance Health, Inc. and Most of Its Subsidiaries**
- Source: The AI Journal | 20251212T170755 | Bullish | Relevance: 100%
- AM Best has affirmed and upgraded various credit ratings for Elevance Health, Inc. and its subsidiaries, including its core Blue Cross Blue Shield-branded entities and Wellpoint Life and Health Insurance Company. The actions reflect the group's very strong balance sheet strength, strong operating performance, and appropriate enterprise risk management. Granular Insurance Company also saw its ratings upgraded due to its strategic importance to Elevance.

**4. Elevance Health (ELV) Stock News Today: ACA Subsidy Deadline Looms, Fitch Affirms A- Rating, and Analysts See Modest Upside (Dec. 12, 2025)**
- Source: ts2.tech | 20251212T162602 | Neutral | Relevance: 100%
- Elevance Health (NYSE: ELV) is navigating market forces including a technical rebound in its shares and the looming expiration of ACA subsidies, which could significantly impact the 2026 healthcare landscape. Fitch has affirmed Elevance Health's A- credit rating with a stable outlook, acknowledging operational pressures while confirming a solid financial profile. Analysts remain broadly constructive on ELV, anticipating modest upside despite policy uncertainties and concerns surrounding 2026 Medicaid margins and potential ACA market disruption.

**5. AM Best affirms Elevance Health ratings, upgrades Anthem units**
- Source: Stock Titan | 20251212T161202 | Bullish | Relevance: 100%
- AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of "a+" (Excellent) for most of Elevance Health, Inc.'s insurance subsidiaries, including core Blue Cross Blue Shield-branded and non-Blue-branded units. Additionally, AM Best upgraded the FSR to A (Excellent) and the Long-Term ICR to "a+" (Excellent) for Wellpoint Life and Health Insurance Company and Wellpoint West Virginia, Inc., collectively known as Anthem Health, due to their strategic importance. Granular Insurance Company also saw its FSR upgraded to A (Excellent) and Long-Term ICR to "a" (Excellent) after being removed from under review with positive implications.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-26 | TD Cowen | $400 | $380 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-26 | TD Cowen | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.6%)
- Blackrock Inc.: 9.2% (+0.6%)
- State Street Corpora: 4.7% (-2.1%)
- Wellington Managemen: 3.0% (+4.8%)
- Price (T.Rowe) Assoc: 2.6% (-27.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +9.3% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.04 suggests fair value with growth premium. Analyst sentiment positive (1 raises, avg +5%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $80.9B |
| Beta | 0.53 |
| 52W Range | $273.71 - $458.75 |
| Short Interest | 1.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.04 |
| Forward P/E | 13.3 |
| Current P/E | 12.0 |
| YoY Growth | -9.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -1.5% to 7.8% (+9.3% in 5 days), confirming momentum buildup. Extended beyond STRENGTH zone (7.8% > 6.0%), caution on chasing. MRS_5 at 5.8% confirms short-term momentum alignment. Outperforming sector by 8.1pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (3.30), confirming momentum. OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 7.81% (CS: 97) | Strong |
| RSI_14 | 68.7 | Neutral |
| MACD Histogram | 3.30 | Bullish |
| vs SMA20 | 1.080x | Above |
| vs SMA50 | 1.070x | Above |
| vs SMA200 | 1.004x | Above |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $359.07
- **Stop Loss:** $339.23 (5.5% risk)
- **Target:** $378.91 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 50
- **Position Value:** $17,953.50
- **Portfolio %:** 17.95%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-01-22 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.94 | $6.03 | +22.0% |
| 2025Q2 | $8.96 | $8.84 | -1.4% |
| 2025Q1 | $11.48 | $11.97 | +4.3% |
| 2024Q4 | $3.85 | $3.84 | -0.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*